http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Young Joo Min,Cheol Won Suh,Keon Uk Park,Sung-Soo Yoon,Chan Hyung Park,Hong Ghi Lee 대한암학회 2003 Cancer Research and Treatment Vol.35 No.1
Purpose: This study was conducted to determine theefficacy and safety of DA-3030 (a recombinant methionylhuman granulocyte colony-stimulating factor, rhG-CSF),after remission induction chemotherapy, in patients withacute myelogenous leukemia (AML).Materials and Methods: After the remission inductionchemotherapy, with idarubicin (12 mg/m2/day for 3 days)and cytarabine (200 mg/m2/day for 7 days), 26 patientswith newly diagnosed AML were assigned to receiveDA-3030 (200μg/m2/day), starting 24 hours after thecompletion of the remission induction chemotherapy,until their neutrophil count recovered to greater than1,000/μL for 3 consecutive days.Results: The median time from the initiation of thechemotherapy to the neutrophil recovery of 1,000/μL was21 days (range, 12∼41). Treatment with DA-3030 was notassociated with significant adverse side effects. The mostfrequently reported side effects were musculo-skeletalpain (13%) and headache (13%).Conclusion: The DA-3030 is a safe rhG-CSF for thetreatment of neutropenia after remission induction chemotherapyin patients with AML. (Cancer ResTreat. 2003;35:66-68)
Gemcitabine Therapy in Patients with Advanced Pancreatic Cancer
( Young Joo Min ),( Kwang Ro Joo ),( Neung Hwa Park ),( Tae Kwon Yun ),( Yang Won Nah ),( Chang Woo Nam ),( Jae Hoo Park ) 대한내과학회 2002 The Korean Journal of Internal Medicine Vol.17 No.4
Background: Advanced, unresectable pancreatic cancer is an extremely aggressive disease. The 5-year survival rate for pancreatic cancer is only less than 5%. Current therapeutic options for patients with locally advanced or metastatic disease are limited.